Peptide half-life explained, with a chart of real half-lives
Reviewed 15 sourcesPublished by PepVault
What a peptide half-life means, why natural peptides last minutes and semaglutide a week, and a chart of real half-lives sourced from FDA labels and studies.

- Last reviewed
- Sources
- 15
- Questions
- 6
- Compounds
- 9
The short answer
A half-life is the time it takes for half of a dose to leave the blood. After one half-life 50% is left, after two 25%, and after about five only 3%. Natural peptides last minutes, because enzymes cut them and the kidneys filter them out. Drugs such as semaglutide grip a blood protein called albumin and last about a week, which is why they are weekly shots.
- Each half-life removes half of what is left, so about five half-lives leave roughly 3% of a dose.
- The body's own GLP-1 lasts 1.5 to 2 minutes; semaglutide, built on it, lasts about a week.
- The long-acting tricks are albumin binding (fatty acids, DAC), PEG and D-amino acids.
- A half-life without a named study, species and route is a guess, however precise it looks.
Evidence: FDA labels (pharmacokinetics measured in people) for every label drug in the chart, human pharmacokinetic studies for CJC-1295 with DAC and ipamorelin, and animal studies only for BPC-157, the semaglutide mini-pig figure and CJC-1295's albumin binding.

What does half-life mean for a peptide?
A half-life is a clock that measures loss, not time on the job. Whatever amount of a peptide is in the blood, one half-life later half of it is gone, and the next half-life takes half of what remained. The level never drops in a straight line: it falls fast while there is a lot to clear and slowly once little is left.
| Half-lives since the dose | Share of the dose still there |
|---|---|
| 1 | 50% |
| 2 | 25% |
| 3 | 12.5% |
| 4 | about 6% |
| 5 | about 3% |
| 7 | under 1% |
That is why pharmacology treats five half-lives as "close to gone". Semaglutide's label puts it in plain numbers: with an elimination half-life of about one week, semaglutide stays in the circulation for about five weeks after the last dose1. The same rule turns tirzepatide's half-life of about 5 days2 into roughly 25 days, and exenatide's 2.4 hours4 into about half a day.
A half-life measures how long a compound stays in the blood, not how strong it is or how long its effect lasts. CJC-1295 with DAC shows the gap: its half-life in healthy adults was 5.8 to 8.1 days, while the growth hormone it released stayed raised for 6 days or more and IGF-1 for 9 to 11 days10.

PepVault for iPhone
Keep your protocol in PepVault
PepVault's Protocol tab draws a modelled level from the doses you log for a single compound logged in mg or mcg with a half-life of 12 hours or more, such as semaglutide or tirzepatide, so a late or skipped dose shows as a dip in the curve.
7 days free on the yearly plan for new subscribers.
Why do natural peptides only last a few minutes?
Two things clear them, and both are fast. The first is enzymes. Blood and tissue are full of peptidases, enzymes that cut peptide chains, and a short natural peptide is an easy target. The body's own GLP-1 has a half-life of 1.5 to 2 minutes, because the enzymes DPP-4 and neutral endopeptidase cut it almost as soon as it is released3. Somatostatin, the hormone octreotide is built on, lasts 1 to 3 minutes5.
The second is the kidney. Its filter lets small molecules pass from the blood into the urine and holds back large ones, and most peptides are small. Exenatide, a 39-amino-acid GLP-1 drug first identified in the Gila monster lizard and about 4.2 kDa in size, is cleared mainly by kidney filtration, studies in animals showed, and lasts 2.4 hours in people, measurable for about 10 hours after a dose4. A 2006 review of half-life strategies names the same pair, fast kidney clearance and enzyme breakdown in the circulation, as the usual reasons a peptide drug is short-lived15.
For the body, short is the point: a hormone that switches off in minutes sends a brief, precise signal. For a drug, it means a shot every few hours, or a molecule rebuilt to last.
How do drug makers stretch a half-life to a week?
Every long-acting peptide on this page uses one of four tricks, and each answers one of the two clearance routes above.
- A fatty acid that grips albumin. Albumin is the most common protein in blood and far too large for the kidney to filter. Attach a fatty acid chain and the peptide rides on albumin, hidden from enzymes and the kidney1. Liraglutide carries a 16-carbon fatty acid, binds albumin and lasts about 13 hours314; semaglutide carries an 18-carbon fatty diacid plus a swapped amino acid at position 8 that blocks DPP-4, and lasts about a week, with over 99% of it bound to albumin1; tirzepatide carries a 20-carbon fatty diacid and lasts about 5 days2.
- DAC, a chemical hook onto albumin. DAC (drug affinity complex) is a reactive group that bonds the peptide to albumin itself. CJC-1295 is the growth-hormone-releasing peptide sermorelin's chain, modified and fitted with this hook; in rats it was found bound to albumin and still in plasma after 72 hours11, and in healthy adults its half-life was 5.8 to 8.1 days10.
- PEG, a long polymer tail. PEG (polyethylene glycol) makes a molecule too bulky to filter and shields it from enzymes. Pegcetacoplan joins two 15-amino-acid peptides to a 40 kDa PEG chain; its median effective half-life is 8.6 days in people with the blood disorder PNH6.
- D-amino acids and a ring. Amino acids come in mirror-image forms, and the body's enzymes are built for the usual L form. Octreotide is a chain of eight amino acids, two of them D forms, closed into a ring by a sulfur bridge; it lasts 1.7 to 1.9 hours against somatostatin's 1 to 3 minutes5.
Not every trick is chemistry on the molecule. Liraglutide's once-daily profile also comes from the molecules clumping together under the skin, which slows their absorption3.
What are the half-lives of common peptides?
Label drugs first, measured in people and stated in the FDA label as of November 2026; research peptides after, with the study, the species and the route. A half-life after a shot under the skin can differ from one after an IV infusion, because absorption takes time.
| Peptide | Half-life | Measured in | Source |
|---|---|---|---|
| GLP-1 (the body's own) | 1.5 to 2 minutes | People | Victoza label3 |
| Somatostatin (the body's own) | 1 to 3 minutes | People | Sandostatin label5 |
| Tesamorelin (Egrifta SV / WR) | 8 / 11 minutes | Healthy adults, one shot under the skin | Egrifta SV and WR labels78 |
| Octreotide (Sandostatin) | 1.7 to 1.9 hours | People | Sandostatin label5 |
| Exenatide (Byetta) | 2.4 hours | People | Byetta label4 |
| Bremelanotide, PT-141 (Vyleesi) | About 2.7 hours (1.9 to 4.0) | People, one shot under the skin | Vyleesi label9 |
| Liraglutide (Victoza, Saxenda) | About 13 hours | People, under the skin | Victoza label3 |
| Tirzepatide (Mounjaro, Zepbound) | About 5 days | People | Mounjaro label2 |
| Semaglutide (Ozempic, Wegovy) | About 1 week | People | Ozempic label1 |
| Pegcetacoplan (Empaveli) | 8.6 days (median) | People with PNH | Empaveli label6 |
| CJC-1295 with DAC | 5.8 to 8.1 days | Healthy adults, under the skin | Teichman 200610 |
| Ipamorelin | 2 hours | Healthy men, IV infusion | Gobburu 199912 |
| BPC-157 | Under 30 minutes | Rats and dogs, IV and into muscle; never measured in people | He 202213 |
Each compound in the library has its own half-life page with the figure, its source and the build-up over a typical schedule: semaglutide, tirzepatide, liraglutide, exenatide, PT-141, tesamorelin, CJC-1295 with DAC, ipamorelin and BPC-157 among them.
How does half-life relate to dosing intervals and steady state?
A labelled interval is chosen so that the level never falls too far between doses. When a new dose arrives before the last one is gone, the two add up, and the level climbs dose by dose until the amount cleared between doses equals the amount added. That plateau is called steady state, and on a fixed schedule the usual rule of thumb is about four to five half-lives to reach it, whatever the interval.
The labels show it. Semaglutide reaches steady-state exposure after 4 to 5 weeks of weekly shots1, and tirzepatide after 4 weeks2. The arithmetic below is general pharmacology from each label's half-life and labelled interval, not a schedule for anyone: how much of one dose is left when the next is due, and how high the plateau sits compared with one dose alone.
| Drug and labelled interval | Half-life | Left of a dose when the next is due | Plateau against a single dose |
|---|---|---|---|
| Exenatide, twice a day (counted as 12 hours apart) | 2.4 hours4 | About 3% | About 1.0 times |
| Liraglutide, once a day | About 13 hours3 | About 28% | About 1.4 times |
| Tirzepatide, once a week | About 5 days2 | About 38% | About 1.6 times |
| Semaglutide, once a week | About 1 week1 | About 50% | About 2 times |
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.
This build-up is why the early weeks on a weekly GLP-1 are not yet the full picture, and why the trials and labels compare people after steady state. It also works in reverse: after the last dose, a weekly drug fades over weeks, not days. Semaglutide's label asks women to stop at least 2 months before a planned pregnancy because of that long washout1.
Commonly reported: on a weekly GLP-1, appetite effects that feel strongest a day or two after the shot and soften before the next, and early weeks that feel milder than later weeks at the same dose, the pattern the build-up curve predicts.
PepVault's Protocol tab draws a modelled level from the doses you log for a single compound logged in mg or mcg with a half-life of 12 hours or more, such as semaglutide or tirzepatide, so a late or skipped dose shows as a dip in the curve. Log it in PepVault
When to get help Before planned surgery or a procedure with sedation, tell your care team you take a GLP-1, because it slows stomach emptying1; before a planned pregnancy, talk to your prescriber early, because the label asks for a 2-month gap1.
Why are half-lives on peptide sites often wrong?
Because most research peptides were never measured in people, and a figure fills the gap anyway. BPC-157 is the clearest case. The 4 to 6 hours in our own library is labelled for what it is: a community estimate for a shot under the skin. The only published pharmacokinetic study, in rats and dogs, found the intact peptide gone with a half-life under 30 minutes, broken into small fragments and single amino acids13. No human half-life has been published.
Species matters even for a well-studied drug. Semaglutide's half-life after an IV dose in mini-pigs was 46.1 hours14, against about a week in people1. A number from an animal study is a clue about the molecule, not the figure for a person.
Before you trust a half-life you find online, run it through four checks:
- Look for the source: an FDA label section 12.3 or a study with a PubMed number. No source means the figure is someone's estimate.
- Check the species. A rat, dog or mini-pig figure does not transfer to people.
- Check the route. Ipamorelin's 2 hours was measured after an IV infusion12; a shot under the skin adds absorption time.
- Check what was measured. The drug's level in the blood and the length of its effect are different clocks, as CJC-1295's days of raised growth hormone show10.
Sources
- Ozempic (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, published June 10, 2026 (sections 5.10, 8.3, 10, 11, 12.1, 12.3). dailymed.nlm.nih.gov
- Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, published September 2, 2026 (sections 10, 12.1, 12.3). dailymed.nlm.nih.gov
- Victoza (liraglutide) injection, prescribing information. Novo Nordisk. DailyMed, published November 17, 2025 (sections 11, 12.1, 12.3). dailymed.nlm.nih.gov
- Byetta (exenatide) injection, prescribing information. AstraZeneca. DailyMed, published September 8, 2025 (section 12.3). dailymed.nlm.nih.gov
- Sandostatin (octreotide acetate) injection, prescribing information. Novartis. DailyMed, published July 24, 2026 (sections 11, 12.3). dailymed.nlm.nih.gov
- Empaveli (pegcetacoplan) injection, prescribing information. Apellis. DailyMed, published August 25, 2026 (sections 11, 12.3). dailymed.nlm.nih.gov
- Egrifta SV (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, published July 31, 2026 (section 12.3). dailymed.nlm.nih.gov
- Egrifta WR (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, published August 3, 2026 (section 12.3). dailymed.nlm.nih.gov
- Vyleesi (bremelanotide) injection, prescribing information. Cosette Pharmaceuticals. DailyMed, published November 9, 2026 (sections 11, 12.3). dailymed.nlm.nih.gov
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PubMed 15817669
- Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PubMed 10496658
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PubMed 36588717
- Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015. PubMed 26308095
- Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006. PubMed 16622600
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.